Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: Current concepts

• Published in: Inflammatory bowel diseases Vol. 13; no. 10; pp. 1293 - 1298
• Main Authors: Levine, Jonathan S., Burakoff, Robert
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.10.2007
• Subjects: 5‐ASA; 6-Mercaptopurine; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; azathioprine; Azathioprine - therapeutic use; Cholagogues and Choleretics - therapeutic use; Colorectal cancer; Colorectal Neoplasms - etiology; Colorectal Neoplasms - prevention & control; Crohn's disease; Data processing; Folic acid; Folic Acid - therapeutic use; Humans; Immunosuppressive Agents - therapeutic use; inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - complications; Inflammatory Bowel Diseases - drug therapy; Intestine; Mercaptopurine - therapeutic use; Mesalamine - therapeutic use; Reviews; Treatment Outcome; Ulcerative colitis; ursodeoxycholic acid; Ursodeoxycholic Acid - therapeutic use; Vitamin B Complex - therapeutic use
• ISSN: 1078-0998; 1536-4844
• DOI: 10.1002/ibd.20186

Ulcerative colitis and Crohn's disease both confer an increased risk of developing colorectal cancer. The use of 5‐aminosalicylate as a remission‐inducing agent has been long accepted. Its use as a potential chemoprophylactic agent has been proposed and is used by some practitioners. This review examines the most recent data on 5‐aminosacilycylate as a chemoprophylactic drug as well as ursodeoxycholic acid, folic acid, azathioprine, and 6‐mercaptopurine. (Inflamm Bowel Dis 2007)